diabetics

Victoza® (liraglutide) Received EU Marketing Authorization

Filed in archive Research , Treatment on July 6, 2009

Victoza® (liraglutide) Received EU Marketing Authorization
Novo Nordisk's prime diabetes drug called Victoza® (liraglutide) has now received narketing authorization by the EU.

Victoza is the first once-daily human glucagon-like peptide-1 (GLP-1) analog developed for the treatment of type 2 diabetes and is now authorized in all 27 European Union member states for:


  • combination treatment with metformin or a sulphonylurea in patients with insufficient glycemic control despite maximal tolerated dose of monotherapy with metformin or sulphonylurea, and

  • combination treatment with metformin and a sulphonylurea or metformin and a thiazolidinedione in patients with insufficient glycemic control despite dual therapy.



Taken once daily,Victoza® is first human Glucagon-Like Peptide-1 (GLP-1) analogue. Find out more at Novo Nordisk.



Permalink: Victoza® (liraglutide) Received EU Marketing Authorization

Tags: diabetes  diabetes  Victoza  liraglutide  novo  nordisk  more  liraglutide+received 

Vote for Victoza® (liraglutide) Received EU Marketing Authorization:

  • Currently 10.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 10.00 out of 4 vote(s) cast.
 
Share It
RSSrss
Google google
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Most Popular   Best of   Blogs, Blogging & Blogosphere   Challenges   Developments   Diabetics' Device   Did you know   Diet   Education   Exercise   Family Matters   Friends   Fun   Information   Information about   Inspiration   Interviews   Lifestyle   Misc   News   Notable